A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Clopixol Acuphase, Clopixol, Clopixol Depot
Synonyms :
zuclopenthixol
Class :
CNS Stimulant agents and Antipsychotics (first generation)
Brand Name :
Clopixol Acuphase, Clopixol, Clopixol Depot
Synonyms :
zuclopenthixol
Class :
CNS Stimulant agents and Antipsychotics (first generation)
Dosage Forms & StrengthsÂ
Oil, Intramuscular:Â
50 mg/ml (1ml)Â
200 mg/ml (1ml)Â
500 mg/ml (1ml)Â Â
Tablet, Oral:Â
10 mgÂ
25 mgÂ
Indicated for Schizophrenia
Oral dose
Initial dose: 10-50 mg orally two-three times in a day, may enhance everyday dose depending on the response, tolerability 10-20 mg increment every two-three days
General therapeutic dose:20-60 mg in a day
Should not generally exceed 100 mg in a day
Intramuscular dose (long-acting zuclopenthixol decanoate)
Before initiation, maintain tolerability with the oral tablet or with short-acting Intramuscular zuclopenthixol acetate
Maintenance dose: 150-300 mg every two-four weeks, may reach the dose upto 600 mg every one-four weeks for certain patients depending on the response, tolerability
Agitation or Aggression linked with schizophrenia/psychotic episodes
Oral dose
Initial dose: 10-50 mg orally two-three times in a day, may enhance everyday dose depending on the response, tolerability 10-20 mg increment every two-three days
General therapeutic dose:20-60 mg in a day
Should not generally exceed 100 mg in a day
Intramuscular dose (short-acting zuclopenthixol decanoate)
General dose: 50-150 mg as one dose, can repeat it every two-three days (certain patients might need another dose for 1-2 days following the initial dose and repeat it every two-three days as needed
Should not exceed 400 mg/ 4 injections throughout the treatment period
The treatment period, Should not exceed two weeks
No safe and efficacious dosage instructions foundÂ
Refer to adult dosingÂ
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
may diminish the therapeutic effect of anti-parkinson agents
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
the efficacy of Dopamine agonists will be decreased when Antipsychotic Agents are used in combination
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
may decrease the therapeutic effect when combined with anti-parkinson agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
anti-Parkinson Agents may diminish the therapeutic effect of anti-psychotic Agents
may decrease the therapeutic effect of anti-Parkinson agents
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may diminish the therapeutic efficacy of each other when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
may enhance the risk of CNS depression when combined
CYP3A strong enhancers of the small intestine may reduce the bioavailability of zuclopenthixol
may have an increasingly adverse effect when combined with antipsychotic agents
antipsychotic agents increase the effect of arrhythmia of saquinavir
Could potentially reduce the therapeutic efficacy of antipsychotic agents
The potential for increased toxicity of Sulpiride could be amplified by the presence of antipsychotic agents
tiopronin: they may increase the toxic effect of antipsychotic agents
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antipsychotic Agents may enhance the adverse/toxic effect of amphetamines
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of amphetamines
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may enhance the hypotensive effect of beta-blockers
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may increase the effect of beta-blockers
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
may reduce the therapeutic effect of antiparkinson drugs
It may enhance the metabolism when combined with dexamethasone
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
may have an increased QTc-prolonging effect when combined with QT-prolonging antipsychotics
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
zuclopenthixol: they may enhance the serum concentration of CYP2D6 Inhibitors
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may diminish the therapeutic effect of the drug
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
when zuclopenthixol is coupled with fentiazac, the risk or severity of hypertension can be raised
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
zuclopenthixol: they may increase the antiplatelet effect of Agents with antiplatelet properties
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
may have an increasingly adverse effect when combined with amphetamines
the metabolism of dihydroergocristine can decrease when combined with zuclopenthixol
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
may have an increased hypotensive effect when combined with beta-blockers
combining isoxicam with zuclopenthixol may increase the risk or severity of hypertension
zuclopenthixol may decrease the antihypertensive activities of muzolimine
the risk or severity of QTc prolongation can be increased when prenylamine is combined with zuclopenthixol
when combined with ivacaftor, there is potential for an increased serum concentration of zuclopenthixol
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
may enhance the risk of hypertension when combined
it may increase the neurotoxic effect of antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
seizure lowering agents increase the toxic or adverse effects of other antipsychotic agents
It may increase the neurotoxic effect of Antipsychotic Agents
it may increase the risk of adverse effect of amphetamines
it may increase the risk of adverse effects of antipsychotic agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
it enhance the neurotoxic (central) effect of antipsychotic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
Serotonergic Agents may enhance the adverse/toxic effect of antipsychotic Agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may enhance the neurotoxic (central) effect of antipsychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
may increase the adverse or toxic effect of anti-psychotic agents
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
antipsychotic agents may enhance the adverse/toxic effect of amphetamines
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
antacids may reduce the absorption of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the risk of adverse effects of antipsychotic agents
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may increase the hypotensive effect of beta-blockersÂ
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may enhance the risk of adverse/toxic effect of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may decrease the absorption of antipsychotic agents
may increase the hypotensive effect of antihypertensives
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the adverse effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the neurotoxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may enhance the adverse/toxic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may diminish the therapeutic effect of antipsychotic agents
may increase the hypotensive effect of blood pressure-lowering agents
may increase the serum concentrations of CYP2D6 inhibitors
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the effect of antipsychotic agents
may increase the risk of adverse effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may increase the neurotoxic effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may enhance the hypotensive effect
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increased neurotoxic effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with antipsychotic agents
may have an increasingly adverse effect when combined with dexmethylphenidate
may increase the QTc-prolonging effect of QT-Prolonging Inhalational Anesthetics
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may enhance the metabolism when combined with zuclopenthixol
it may diminish the metabolism when combined with zuclopenthixol
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
The Therapeutic efficacy of quinagolide might be reduced
may enhance the QTc-prolonging effect of each other when combined
Could potentially amplify the toxicity of antipsychotic agents
lithium: they may increase the neurotoxic effect of antipsychotic agents
mianserin: they may decrease the therapeutic effect of antipsychotics
when etafedrine is combined with zuclopenthixol, its efficacy will decrease
when combined with asunaprevir, the metabolism of zuclopenthixol may be decreased
there can be risk of hypertension can be raised when sulindac is used in combination
may have an increased neurotoxic effect when combined with antipsychotic agents
Actions and Spectrum:Â
zuclopenthixol is an antipsychotic medication that belongs to the class of drugs known as thioxanthenes. It is primarily used to treat schizophrenia and other psychotic disorders.Â
The mechanism of action of zuclopenthixol is not fully understood, but it is generally believed to work by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter that is generally involved in the regulation of behavior, mood, and cognition. By blocking dopamine receptors, zuclopenthixol can help to reduce the symptoms of psychosis, like hallucinations and delusions.Â
zuclopenthixol is also thought to have some activity at other receptors in the brain, including serotonin and adrenergic receptors. This may contribute to its overall effectiveness in treating psychotic disorders.Â
The spectrum of zuclopenthixol refers to the range of symptoms and conditions it can treat. As an antipsychotic medication, zuclopenthixol is primarily used to treat symptoms of psychosis, including hallucinations, delusions, disordered thinking, and agitation. It may also treat other psychiatric disorders like bipolar disorder and severe anxiety.Â
Frequency defined:Â Â Â
>10%:Â
DrowsinessÂ
Hypertonia Â
Anxiety Â
Dizziness Â
Insomnia Â
Tremor Â
Weakness Â
Accommodation disturbance Â
Xerostomia  Â
1% to 10%:Â
Tachycardia Â
Orthostatic hypotensionÂ
PalpitationÂ
Depression Â
Agitation Â
Abnormal dreams Â
Malaise Â
ConfusionÂ
Apathy Â
Vomiting Â
Diarrhea Â
Nausea Â
Urinary disorder Â
Ejaculatory disorder
Black Box Warning:Â
zuclopenthixol has a black box warning, the most severe warning that the US Food and Drug Administration (FDA) can require. The black box warning for zuclopenthixol relates to an enhanced mortality risk in elderly patients with dementia-related psychosis.Â
Older patients with dementia-related psychosis who are treated with antipsychotic medications like zuclopenthixol are at an enhanced risk of death compared to those who are not treated with these medications. This risk appears to be highest in the first few weeks of treatment.Â
zuclopenthixol is not approved for the treatment of dementia-related psychosis, and the black box warning advises healthcare professionals to carefully consider the risks and benefits of using antipsychotic medications in elderly patients with this condition.Â
The black box warning also advises that zuclopenthixol should be generally used cautiously in patients with a history of seizures, as it may lower the seizure threshold and increase the risk. Additionally, zuclopenthixol may cause other side effects, including sedation, weight gain, and movement disorders. Healthcare professionals should monitor patients closely for these side effects, adjust the dosage, or switch to a different medication if necessary.Â
Contraindication/Caution:Â
ContraindicationÂ
zuclopenthixol has several contraindications, so it should not be used in certain patients or conditions. These contraindications include:Â
CautionÂ
zuclopenthixol has several cautions, which means it should be used cautiously in certain patients or conditions. These cautions include:Â
Pregnancy consideration: Studies with animal reproduction reported adverse events in newborns due to zuclopenthixol. Â
Lactation: excretion of zuclopenthixol in breast milk is not known. Â
Pregnancy category:Â
Â
Pharmacology:Â
zuclopenthixol is an antipsychotic medication that belongs to the class of drugs known as thioxanthenes. It blocks dopamine receptors in the brain, which regulate mood, behavior, and perception. By blocking these receptors, zuclopenthixol can help to decrease the symptoms of psychosis, such as hallucinations, delusions, and disordered thinking.Â
In addition to its effects on dopamine receptors, zuclopenthixol also has some affinity for other receptors in the brain, including serotonin and noradrenaline receptors. These actions may contribute to its efficacy in treating certain psychiatric and neurological conditions, such as bipolar disorder and Tourette’s syndrome.Â
Pharmacodynamics:Â
Mechanism of action: zuclopenthixol is an antipsychotic medication that works primarily by blocking dopamine receptors in the brain. Dopamine is a neurotransmitter involved in regulating mood, behavior, and perception, and abnormalities in dopamine signaling have been typically implicated in the development of psychotic disorders such as schizophrenia.Â
Pharmacokinetics:Â
AbsorptionÂ
zuclopenthixol is readily absorbed from the gastrointestinal tract after oral administration. The absorption is relatively rapid, with peak plasma levels reached within 2 to 4 hours. The bioavailability of zuclopenthixol is approximately 60-70%, and food does not significantly affect its absorption.Â
DistributionÂ
zuclopenthixol has a large volume of distribution, indicating that it is generally distributed throughout the body. The drug is highly protein-bound (greater than 99%), primarily to albumin. Zuclopenthixol crosses the blood-brain barrier and can exert its effects on the central nervous system.Â
MetabolismÂ
zuclopenthixol is extensively metabolized in the liver via oxidation and conjugation. The primary metabolic pathway is oxidation by the cytochrome P450 system, particularly the CYP1A2 and CYP2D6 enzymes, which produce the major metabolite, 7-hydroxy-zuclopenthixol. This metabolite has similar pharmacological activity as the parent drug and contributes to its overall effects.Â
Elimination and ExcretionÂ
The elimination half-life of zuclopenthixol is approximately 30 hours, which is relatively long compared to other antipsychotic medications. The drug and drug metabolites are excreted in the urine, with only a tiny fraction in the feces.Â
Administration:Â
Oral administrationÂ
zuclopenthixol is available as an injection and as a tablet for oral administration. The dosing and administration of zuclopenthixol may vary depending on the indication and the patient’s needs.Â
When administering zuclopenthixol injection, healthcare professionals should follow proper techniques and ensure the injection is given into a large muscle mass, like the gluteal muscle. The injection should be given slowly, and the patient should be observed for nearly 30 minutes to monitor for adverse reactions.Â
zuclopenthixol tablets should be taken orally with or without food, as directed by the healthcare professional. The tablets should be generally swallowed whole with water and not crushed, chewed, or broken.Â
The zuclopenthixol dosage may need to be adjusted based on the patient’s response to treatment, age, weight, and other factors. It is essential to follow the healthcare professional’s instructions and to not change the dosage or stop taking the medication without consulting with the healthcare professional first.Â
Patients taking zuclopenthixol should be monitored for side effects, including sedation, weight gain, movement disorders, and changes in blood pressure and heart rate. Patients should also be generally monitored for signs, symptoms of an allergic reaction, like the difficulty breathing, and swelling of the lips, tongue/throat.Â
Overall, the administration of zuclopenthixol should be carefully monitored and managed by a healthcare professional with experience in the use of antipsychotic medications.Â
Patient information leafletÂ
Generic Name: zuclopenthixolÂ
Why do we use zuclopenthixol?Â
zuclopenthixol is an antipsychotic medication that is used to treat several psychiatric and neurological conditions, including:Â
It is important to note that zuclopenthixol should be generally used under the supervision of a physician with experience using antipsychotic medications. The dosage, duration of treatment should be carefully monitored and adjusted as needed based on the patient’s response to treatment and any side effects that may occur.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
